Want to see HK:2410 full AI Analyst Report?
2410 Stock Chart & Stats
HK$12.93
-HK$7.80(-21.14%)
At close: 4:00 PM EST
HK$12.93
-HK$7.80(-21.14%)
Day’s Range― - ―
52-Week RangeHK$5.35 - HK$22.56
Previous CloseN/A
Volume117.00K
Average Volume (3M)14.02M
Market Cap
HK$2.53B
Enterprise ValueHK$2.29K
Total Cash (Recent Filing)HK$158.31M
Total Debt (Recent Filing)HK$120.72M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding380,065,830
10 Day Avg. Volume4,737,687
30 Day Avg. Volume14,019,805
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)15.38
Price to Sales (P/S)0.00
P/FCF Ratio-17.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)HK$504.00M
Bulls Say, Bears Say
Bulls Say
Narrower Net LossesThe substantial reduction in annual net losses suggests some progress in cost control and operating discipline. Although profitability remains distant, continued loss reduction could extend the company’s financial runway and support a future path toward sustainable economics.
Positive Equity And Lower DebtPositive shareholders’ equity and reduced debt provide a more stable capital base than in earlier periods, when equity was negative and leverage was extreme. This improves financial flexibility, although continuing losses could erode that support.
Improving Cash BurnThe reduction in operating and free cash outflows indicates progress in controlling cash consumption. While the company remains dependent on external funding, a sustained improvement in burn rates would lengthen liquidity runway and reduce financing pressure.
Bears Say
Minimal Commercial RevenueThe absence of meaningful revenue shows that the business has not yet established a commercial earnings base. This limits internal funding capacity, increases dependence on financing or partnerships, and leaves future value highly dependent on successful product development and commercialization.
Persistent Large LossesSustained large losses, together with negative gross profit in 2025, indicate that profitability has not yet demonstrated a durable inflection. Continued losses can erode equity, constrain investment capacity, and raise the amount of capital needed before products generate returns.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the company is not self-funding its activities. Unless revenue or margins improve materially, it will likely need external capital or balance-sheet resources to maintain operations, creating ongoing funding and dilution risk.
TYK Medicines, Inc. Class H News
2410 FAQ
What was TYK Medicines, Inc. Class H’s price range in the past 12 months?
TYK Medicines, Inc. Class H lowest stock price was HK$5.35 and its highest was HK$22.56 in the past 12 months.
What is TYK Medicines, Inc. Class H’s market cap?
TYK Medicines, Inc. Class H’s market cap is HK$2.53B.
When is TYK Medicines, Inc. Class H’s upcoming earnings report date?
TYK Medicines, Inc. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 220 days.
How were TYK Medicines, Inc. Class H’s earnings last quarter?
TYK Medicines, Inc. Class H released its earnings results on Aug 17, 2026. The company reported -HK$0.082 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TYK Medicines, Inc. Class H overvalued?
According to Wall Street analysts TYK Medicines, Inc. Class H’s price is currently Overvalued.
Does TYK Medicines, Inc. Class H pay dividends?
TYK Medicines, Inc. Class H does not currently pay dividends.
What is TYK Medicines, Inc. Class H’s EPS estimate?
TYK Medicines, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TYK Medicines, Inc. Class H have?
TYK Medicines, Inc. Class H has 380,065,830 shares outstanding.
What happened to TYK Medicines, Inc. Class H’s price movement after its last earnings report?
TYK Medicines, Inc. Class H reported an EPS of -HK$0.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.372%.
Which hedge fund is a major shareholder of TYK Medicines, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2410
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TYK Medicines, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.06%
Trailing 12-Months
Company Description
TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primary drug candidate, TY-9591, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is being developed to treat non-small cell lung cancer (NSCLC) with EGFR mutations that has metastasized to the brain, as well as locally advanced or metastatic NSCLC characterized by the EGFR L858R mutation. Beyond its lead candidate, TYK Medicines maintains a diverse pipeline of other investigational therapies. These include TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor designed for solid tumors such as breast and prostate cancer. Another compound, TY-2136b, is an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor also aimed at solid tumors. The company is advancing TY-2699a, a selective CDK7 inhibitor, and TY-0540, a selective CDK2/4/6 inhibitor, both targeting advanced or metastatic solid malignancies. Further, the pipeline features TY-4028, an oral exon 20 insertion tyrosine kinase inhibitor (TKI) specifically addressing locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 or HER2 exon 20 insertions. TY-1091 is a potent and selective rearranged during transfection proto-oncogene (RET) inhibitor, under development for advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer with RET gene mutation, and other solid tumors presenting RET gene alterations. Other promising programs include TY-1054, an oral yes-associated protein-transcriptional enhanced associate domain inhibitor for various cancers; TY-1210, a selective CDK2 inhibitor for solid tumors; TY-0609, a selective CDK4 inhibitor also for cancer therapy; and TY-3200, an innovative EGFR degrader. Established in 2017, the enterprise operates from its main office located in Huzhou, China.
Technical Analysis
Peijia Medical Ltd.
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Viva Biotech Holdings
―
Clover Biopharmaceuticals Ltd.
―
Jacobson Pharma Corporation Limited
―